Evidence map›Paper›PMID 42298372›Full record

ArticleProtein science : a publication of the Protein Society2026

Substrate scope of ancestral versus modern family-1 glycosidases.

Luis I Gutierrez-Rus, Dušan Petrović, Pascal Schneider, Katja Zorn, Gloria Gamiz-Arco, Rocío Romero-Zaliz, Ignacio Suarez-Martin, Leonardo De Maria, Francesco Falcioni, Valeria A Risso and 2 more

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Substrate scope of ancestral versus modern family-1 glycosidases.Protein science : a publication of the Protein Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Luis I Gutierrez-RusDepartamento de Quimica Fisica, Facultad de Ciencias, Unidad de Excelencia de Quimica Aplicada a Biomedicina y Medioambiente (UEQ), Universidad de Granada, Granada, Spain.
Dušan PetrovićDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Pascal SchneiderDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Katja ZornDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Gloria Gamiz-ArcoDepartamento de Quimica Fisica, Facultad de Ciencias, Unidad de Excelencia de Quimica Aplicada a Biomedicina y Medioambiente (UEQ), Universidad de Granada, Granada, Spain.ORCID 0000-0001-9883-3542
Rocío Romero-ZalizCentro de Investigación en Tecnologías de la Información y las Telecomunicaciones (CITIC-UGR), Universidad de Granada, Granada, Spain.
Ignacio Suarez-MartinDepartamento de Quimica Fisica, Facultad de Ciencias, Unidad de Excelencia de Quimica Aplicada a Biomedicina y Medioambiente (UEQ), Universidad de Granada, Granada, Spain.
Leonardo De MariaMedicinal Chemistry, Research and Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Francesco FalcioniEarly Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Valeria A RissoDepartamento de Quimica Fisica, Facultad de Ciencias, Unidad de Excelencia de Quimica Aplicada a Biomedicina y Medioambiente (UEQ), Universidad de Granada, Granada, Spain.
Martin A HayesDiscovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Jose M Sanchez-RuizDepartamento de Quimica Fisica, Facultad de Ciencias, Unidad de Excelencia de Quimica Aplicada a Biomedicina y Medioambiente (UEQ), Universidad de Granada, Granada, Spain.ORCID 0000-0002-9056-3928

Funding

AstraZenecaMinisterio de Ciencia, Innovación y Universidades PID2021-124534OB-100
6 · The paper itself

Abstract

Experimental studies support that protein engineering based on ancestral sequence reconstruction often leads to variants with biotechnologically useful biomolecular properties. These may include high stability, enhanced conformational flexibility and a modified catalysis range. Carbohydrate-active enzymes have numerous applications related to the degradation and synthesis of carbohydrates and glycoconjugates. Herein, we explore how ancestral reconstruction impacts the substrate scope of glycosidases, highly diverse enzymes that catalyze the hydrolysis of glycosidic bonds in all living cells and find applications as catalysts of the synthetic reaction. To this end, we screened 291 potential glycosidase substrates for degradation by both a modern family-1 glycosidase from the halothermophilic bacterium Halothermothrix orenii and a putative ancestral family-1 glycosidase derived from sequence reconstruction of a bacterial-eukaryotic common ancestor. The modern enzyme is the better catalyst for many substrates, but the ancestral glycosidase is more efficient with flavonoid glycosides bearing large-aglycone moieties. Analysis of the catalytic parameters for a selected set of substrates, alongside analysis of the library data using a supervised learning algorithm, supports the hypothesis that the modern enzyme tends to become less catalytically efficient with increasing substrate size, while this trend is not observed for the ancestral glycosidase. Molecular modeling supports that the ancestral catalysis pattern is linked to the existence of a highly flexible region of the protein and a cavity capable of accommodating large aglycones. Our results and analyses provide guidelines for the engineering of enzymes for the synthesis and hydrolysis of large glycoconjugates.

Indexed as

Bacterial ProteinsGlycoside HydrolasesEvolution, MolecularModels, MolecularSubstrate SpecificityBacterial ProteinsGlycoside Hydrolasesancestral sequence reconstructionco‐foldingconformational flexibilityenzyme promiscuitysubstrate scope: glycosidasesTIM‐barrel fold

Identifiers

PMID42298372
PMCPMC13269172

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.